about
Antibody mediated rejection in pig-to-nonhuman primate xenotransplantation models.Xenotransplantation-current status and future perspectives.Xenotransplantation as a model of integrated, multidisciplinary researchDe novo anti-HLA antibody responses after renal transplantation: detection and clinical impact.Endothelial glycocalyx biomarkers increase in patients with infection during Emergency Department treatment.Resistin and NGAL are associated with inflammatory response, endothelial activation and clinical outcomes in sepsis.Innate inflammatory cells are not responsible for early death of donor myoblasts after myoblast transfer therapy.In vitro and in vivo immunomodulatory effects of cobalt protoporphyrin administered in combination with immunosuppressive drugs.In vitro and in vivo effects of the carbon monoxide-releasing molecule, CORM-3, in the xenogeneic pig-to-primate context.Cobalt protoporpyhrin reduces caspase-3,-7 enzyme activity in neonatal porcine islets, but does not inhibit cell death induced by TNF-alpha.Neutrophil activation during acute human anaphylaxis: analysis of MPO and sCD62L.Serum mast cell tryptase measurements: Sensitivity and specificity for a diagnosis of anaphylaxis in emergency department patients with shock or hypoxaemia.Distinct inflammatory responses differentiate cerebral infarct from transient ischaemic attack.Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.A comparison between real-time quantitative PCR and DNA hybridization for quantitation of male DNA following myoblast transplantation.Effects of Long-term Administration of High-dose Recombinant Human Antithrombin in Immunosuppressed Primate Recipients of Porcine XenograftsGlycocalyx biomarker syndecan-1 is a stronger predictor of respiratory failure in patients with sepsis due to pneumonia, compared to endocanSeven Days of Low-Dose Orally Administered Murine Type I Interferon Does Not Cause Priming In VivoLow-Dose Orally Administered Type I Interferon Reduces Splenic B Cell Numbers in MiceEfficacy of Low-Dose Oral Use of Type I Interferon in Cytomegalovirus Infections In VivoBolus therapy with 3% hypertonic saline or 0.9% saline in emergency department patients with suspected sepsis: A pilot randomised controlled trial
P50
Q36173094-815BC6CB-2053-4DD1-ACBD-6EE28FFF9E99Q36488558-7CDA37D0-9433-4B08-95F9-529BB6EE04BEQ37137178-95E2AF91-80D6-4F47-B2AE-DA99BBE6C57DQ37323149-F785FDFC-2A2D-4153-9BE9-2A2B0521CEC1Q40087305-57BD2CAC-C540-4C50-866D-08A16AA0DE74Q40244639-A643F543-4FF5-41FE-AEA7-27067A265E3AQ40540729-C15CE098-9CCD-482D-87DF-7392717907F1Q42936230-7525639A-0E39-4A53-A7AE-6C834C823FEEQ46037822-91450372-7D4C-497D-8ACA-C7A232B92A78Q46345374-29EF0214-4934-431C-9992-4515E1B5DED9Q48185662-8C183786-3FD2-4EA6-871C-727EFE0861F7Q48377828-7B787819-892D-4F29-85F4-D08B5FEDA37FQ51436813-57DD380F-021B-43F7-A3C0-A67A1E65EA71Q54421148-B4AC89FF-BBD8-427D-A126-8A6BE3A0EC74Q54682334-B2B4E2C2-2D89-4BB5-902F-A8913547C9A8Q58004355-C4B7392D-8086-4369-A619-3C81B04FFE8AQ63464486-9BB8B8A0-1853-4040-8DBC-81535AFCC4A7Q63464491-C6A4B19A-5081-47C4-940F-CC8A77188B1BQ63464492-F5FFBCC0-54A0-4DE1-81CB-48D78356C9E9Q63464493-5C2BD792-E813-4D36-89D3-038EFACE7FA6Q92896611-5661F807-A0E0-43C3-B1D0-18C596D97D78
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Erika Bosio
@ast
Erika Bosio
@en
Erika Bosio
@es
Erika Bosio
@nl
Erika Bosio
@sl
type
label
Erika Bosio
@ast
Erika Bosio
@en
Erika Bosio
@es
Erika Bosio
@nl
Erika Bosio
@sl
prefLabel
Erika Bosio
@ast
Erika Bosio
@en
Erika Bosio
@es
Erika Bosio
@nl
Erika Bosio
@sl
P106
P1153
10044774300
57192390839
P21
P31
P496
0000-0001-9985-7829